Skip to main content
Journal cover image

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.

Publication ,  Journal Article
Ashley, DM; Sampson, JH; Archer, GE; Batra, SK; Bigner, DD; Hale, LP
Published in: J Neuroimmunol
September 1997

An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced CD8+ cytotoxic T-lymphocytes against EGFRvIII bearing syngeneic B16-F10 melanoma or 560 astrocytoma cells (H-2b), but not against allogeneic NR6 cells (H-2q) also bearing EGFRvIII significant NK cell activity was also noted in vitro. Vaccination protected against intracranial challenge with EGFRvIII-positive tumor, with 50% long term survival. In vivo depletions of effector cell subsets demonstrated the requirements for both CD8+ and CD4+ T-cells but not NK cells in producing this protective effect. These data demonstrate the generation of significant, antigen-specific and MHC class I-restricted cytotoxic immune responses which are effective against tumors present in the CNS.

Duke Scholars

Published In

J Neuroimmunol

DOI

ISSN

0165-5728

Publication Date

September 1997

Volume

78

Issue

1-2

Start / End Page

34 / 46

Location

Netherlands

Related Subject Headings

  • Tumor Cells, Cultured
  • Transfection
  • Survival Analysis
  • Neurology & Neurosurgery
  • Neoplasm Transplantation
  • Mutation
  • Mice
  • Immunization
  • Histocompatibility Antigens Class I
  • Genetic Techniques
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ashley, D. M., Sampson, J. H., Archer, G. E., Batra, S. K., Bigner, D. D., & Hale, L. P. (1997). A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. J Neuroimmunol, 78(1–2), 34–46. https://doi.org/10.1016/s0165-5728(97)00080-5
Ashley, D. M., J. H. Sampson, G. E. Archer, S. K. Batra, D. D. Bigner, and L. P. Hale. “A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.J Neuroimmunol 78, no. 1–2 (September 1997): 34–46. https://doi.org/10.1016/s0165-5728(97)00080-5.
Ashley, D. M., et al. “A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.J Neuroimmunol, vol. 78, no. 1–2, Sept. 1997, pp. 34–46. Pubmed, doi:10.1016/s0165-5728(97)00080-5.
Journal cover image

Published In

J Neuroimmunol

DOI

ISSN

0165-5728

Publication Date

September 1997

Volume

78

Issue

1-2

Start / End Page

34 / 46

Location

Netherlands

Related Subject Headings

  • Tumor Cells, Cultured
  • Transfection
  • Survival Analysis
  • Neurology & Neurosurgery
  • Neoplasm Transplantation
  • Mutation
  • Mice
  • Immunization
  • Histocompatibility Antigens Class I
  • Genetic Techniques